De patienter, der fik lægemidlet, havde i gennemsnit 0, 84 recidiver pr. år, mens de patienter, der fik placebo, havde 1, 27 recidiver pr. år.
In patients with relapsing remitting MS, Extavia was more effective than placebo in reducing the number of annual relapses: patients receiving the medicine had on average 0.84 relapses a year, when patients on placebo had 1.27 relapses.